7 Things You Need to Know About the Upcoming Allvue (ALVU) IPO

Allvue (NYSE: ALVU), the provider of financial technology for investment companies and managers, is preparing to go public next week. Here are key factors about the upcoming Allvue IPO.

1. Allvue IPO Date - Allvue will go public on September 29. Allvue stock will start trading under the ticker symbol “ALVU” on the New York Stock Exchange (NYSE). Typically, shares that make their public stock market debuts start trading between 10AM-2PM ET.

2. Allvue IPO Pricing - The company priced its shares between $17.00 and $19.00.

3. Shares Offered - Allvue has filed to sell 15,300,000 shares. The S-1 filing shows the number of outstanding shares after IPO offering would be 85,219,062.

4. Allvue IPO Valuation - The fintech company is seeking a valuation of between $1.45 billion to $1.62 billion, based on the indicated share pricing. Allvue is seeking to raise up to $290.7 million via the IPO and will use the raised proceeds to acquire newly-issued units in Bluefin Topco, which was formed in 2019 to serve as a holding company in connection with Vista’s acquisition of Black Mountain Systems.

5. Allvue Ownership - The fintech company was established in 2019 through the merger of Black Mountain Systems and AltaReturn, both owned by Vista Equity Partners (over $75 billion in assets under management), which will control approximately 67.2% of the voting power post IPO. Vista owns 99.5% prior to the offering.

6. Allvue IPO Underwriters - Goldman Sachs, Barclays, and Credit Suisse are the main underwriters for the IPO. Deutsche Bank Securities, RBC Capital Markets and Truist Securities are joint bookrunning managers, while Piper Sandler, Stifel, Cabrera, CastleOak, C.L. King & Associates, Mischler, and Telsey Advisory Group are acting as co-managers for the IPO.

7. Allvue Financials - Allvue reported a net loss of $20.8 million on sales of $71.3 million for the first half of 2021. This compares to a loss of $14.5 million on sales of $62.5 million recorded in the same period a year ago. ARR jumped 31.4% for H1 2021 compared to the end of the prior year-period. Adjusted EBITDA margin for the same period was 16.4%.

You May Also Be Interested In

• Scilex's (SCLX) Semnur Pharmaceuticals to Go Public via Merger with Denali Capital Acquisition Corp. (Nasdaq: DECA)
• Futures lower, Fed's Powell to speak, Boeing plea deal - what's moving markets
• Masimo Corp. (MASI) Issues Response to "Latest Politan Fictions"